Cipla Therapeutics and SIGA Technologies Announce Strategic Partnership to support innovation and provide access to novel antibacterial drugs against biothreats Kumar Jeetendra | March 23, 2021 March 23, 2021, MUMBAI – Cipla Therapeutics, an affiliate of Cipla Limited (BSE: 500087; NSE: CIPLA EQ; referred to as “Cipla”) and SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market announced entering into a strategic partnership to deliver sustained innovation and access to novel antibacterial drugs, particularly …
Roche receives Emergency Use Authorisation in India for its investigational Antibody Cocktail used in the treatment of Covid-19 Kumar Jeetendra | May 5, 2021 Roche receives Emergency Use Authorisation in India for its investigational Antibody Cocktail (Casirivimab and Imdevimab) used in the treatment of Covid-19 Casirivimab and Imdevimab is indicated for the treatment of mild to moderate Covid-19 in high-risk patients Partners with Cipla for pan-India distribution At a global level, Roche and its partner Regeneron are collaborating to …
Cipla Enters into a Licensing Agreement with Lilly to Expand Access to COVID-19 Treatment in India Kumar Jeetendra | May 10, 2021 Mumbai, India, May 10, 2021: Cipla Limited (BSE: 500087 | NSE: CIPLA EQ, hereafter referred to as “Cipla”) today announced it has signed a royalty-free, non-exclusive voluntary licensing agreement with Eli Lilly and Company, USA for the manufacture and commercialization of the drug baricitinib for Covid-19 indication. Baricitinib was issued a restricted emergency use approval …
Cipla launches ‘ViraGen’ a polymerase chain reaction (Covid-19 RT-PCR) test Kumar Jeetendra | May 20, 2021 Mumbai, India; May 20 2021: Cipla Limited (BSE: 500087; NSE: CIPLA EQ, referred to as “Cipla”) today announced the commercialisation of a polymerase chain reaction (RT-PCR) test kit ‘ViraGen’ for COVID-19 in India, in partnership with Ubio Biotechnology Systems Pvt. Ltd. ViraGen is Cipla’s third offering in the Covid-19 testing segment. Cipla already has partnerships …
Roche’s Antibody Cocktail (Casirivimab and Imdevimab) is now available in India, Cipla to market it pan-India Kumar Jeetendra | May 24, 2021 Mumbai, 24 May 2021: Roche India and Cipla Limited (BSE: 500087; NSE: CIPLA EQ, referred to as “Cipla”) today announced that the first batch of the Antibody Cocktail (Casirivimab and Imdevimab) is now available in India while a second batch will be made available by mid-June. In total they can potentially benefit 200,000 patients as …
Pharma Majors Collaborate for Clinical Trial of Investigational Oral Anti-Viral Drug Molnupiravir for COVID-19 Kumar Jeetendra | June 29, 2021 India. June 29, 2021 – Cipla Limited (BSE: 500087; NSE: CIPLA EQ, referred to as “Cipla”), Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, hereafter referred to as “Dr. Reddy’s”), Emcure Pharmaceuticals Limited (hereafter referred to as “Emcure”), Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, …
Cipla launches initiative to improve access to nebulisers for acute asthma management in primary health care centres of rural India Kumar Jeetendra | December 10, 2021 Mumbai, 10th December 2021: Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) announced a first-of-its-kind initiative to improve access to nebulization therapy specifically for patients in the rural sections of the country. With Cipla’s unmatched presence across the care continuum and a wide range of drug-device combinations and treatments, the …
Cipla Launches ‘RT Direct’ Multiplex real time PCR kit for Covid-19 RNA extraction free kit to deliver results in just 45 Min Kumar Jeetendra | May 10, 2022 Mumbai, India; May 10, 2022: Cipla Limited (BSE: 500087; NSE: CIPLA EQ, referred to as “Cipla”) today announced the commercialisation of ‘RT-Direct’ multiplex COVID-19 RT PCR Test kit in India, in partnership with Genes2Me Pvt. Ltd. With this, Cipla is expanding its diagnostics offering to bring more advanced and innovative products. Cipla will be responsible …
Cipla scored highest among pharma companies in CRISIL’s Sustainability Rating 2022 Kumar Jeetendra | May 25, 2022 Mumbai, India; May 25, 2022: Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) announced today that is has been rated ‘STRONG’ in the Sustainability Yearbook 2022 released by CRISIL, a leading rating agency in India. Based on the fiscal 2021 data, CRISIL analysed 586 companies across 53 sectors for over …
Cipla adds capacity of captive renewable energy power plant in Maharashtra & Karnataka Kumar Jeetendra | June 3, 2022 India; June 2, 2022: Cipla Limited (BSE: 500087; NSE: CIPLA EQ) referred to as “Cipla” today announced the commercial operation of additional capacity of captive renewable energy power plant in Maharashtra & Karnataka. In Jan’21, Cipla had commissioned 30 MWp solar project at Tuljapur, and now further added 16 MWp of solar capacity for supplying …
Cipla signs agreement for acquisition of 21.05% stake in Achira Labs to develop affordable, innovative medical kits in India Kumar Jeetendra | June 17, 2022 Mumbai, India; June 17, 2022: Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) announced today that it has signed definitive agreements for acquisition of 21.05% stake (on a fully diluted basis) for an amount of INR 25 crores (approx.) in Achira Labs Private Limited (hereafter referred to as “Achira”) engaged …
Cipla Health signs agreement to acquire Endura Mass Kumar Jeetendra | July 14, 2022 Mumbai, India; July 14, 2022: Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Company” or “Cipla”) announced today that Cipla Health Limited (CHL), wholly owned subsidiary and consumer healthcare arm of the Company has signed definitive agreements for acquisition of Endura Mass, a renowned nutritional supplement brand in the category of …
